Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States.
暂无分享,去创建一个
W. Wilson | E. Jaffe | S. Pittaluga | H. Heslop | C. Rooney | C. Bollard | M. Bishop | J. Cohen | M. Cairo | S. Gottschalk | P. Burbelo | S. Straus | Siu-Ping Turk | R. Little | D. Fowler | A. Wayne | J. Dale | N. El-Mallawany | C. Sportés | R. Fulton | V. Rao | A. Marques
[1] C. Bollard,et al. Long-term remission in a child with refractory EBV+ hydroa vacciniforme-like T-cell lymphoma through sequential matched EBV+-related allogeneic hematopoietic SCT followed by donor-derived EBV-specific cytotoxic T-lymphocyte immunotherapy , 2011, Bone Marrow Transplantation.
[2] W. Wilson,et al. disease: a 28-year experience in the United States Characterization and treatment of chronic active Epstein-Barr virus , 2011 .
[3] T. Okamura,et al. Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection , 2011, Bone Marrow Transplantation.
[4] S. Calattini,et al. Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders by using Immuno-FISH. , 2010, Blood.
[5] Hao Liu,et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. , 2010, Blood.
[6] Y. Nishiyama,et al. Quantitative analysis of Epstein-Barr virus (EBV)-related gene expression in patients with chronic active EBV infection. , 2010, The Journal of general virology.
[7] E. Jaffe,et al. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] T. Pierson,et al. Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay. , 2009, Virology.
[9] O. Arisaka,et al. Chronic active Epstein–Barr virus infection with mosquito allergy successfully treated with reduced‐intensity unrelated allogeneic bone marrow transplantation in a boy , 2009, Pediatric transplantation.
[10] K. Kawa,et al. Allogeneic hematopoietic stem cell transplantation for Epstein–Barr virus‐associated T/natural killer‐cell lymphoproliferative disease in Japan , 2008, American journal of hematology.
[11] K. Yamaguchi,et al. Two cases of chronic active Epstein–Barr virus infection in which EBV‐specific cytotoxic T lymphocyte was induced after allogeneic bone marrow transplantation , 2008, Pediatric transplantation.
[12] D. de Jong,et al. Poor outcomes of chronic active Epstein-Barr virus infection and hemophagocytic lymphohistiocytosis in non-Japanese adult patients. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] S. Kojima,et al. Clinical and virological characteristics of 15 patients with chronic active Epstein-Barr virus infection treated with hematopoietic stem cell transplantation. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] Chung-Che Chang,et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. , 2007, Blood.
[15] M. Asaka,et al. Successful Reduced-Intensity Stem Cell Transplantation With Cord Blood for a Poor-Prognosis Adult with Refractory Chronic Active Epstein-Barr Virus Infection , 2007, International journal of hematology.
[16] T. Ariga,et al. Successful report of reduced-intensity stem cell transplantation from unrelated umbilical cord blood in a girl with chronic active Epstein-Barr virus infection. , 2006, Journal of pediatric hematology/oncology.
[17] H. Kimura. [Chronic active EBV infection]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.
[18] H. Takada,et al. Successful umbilical cord blood transplantation for severe chronic active Epstein‐Barr virus infection after the double failure of hematopoietic stem cell transplantation , 2005, American journal of hematology.
[19] H. Kanegane,et al. Proposed guidelines for diagnosing chronic active Epstein‐Barr virus infection , 2005, American journal of hematology.
[20] S. Kojima,et al. Differences between T cell-type and natural killer cell-type chronic active Epstein-Barr virus infection. , 2005, The Journal of infectious diseases.
[21] T. Tsurumi,et al. Quantitative analysis of Epstein-Barr virus (EBV)-specific CD8+ T cells in patients with chronic active EBV infection. , 2004, The Journal of infectious diseases.
[22] C. Nakaseko,et al. Successful control of Epstein–Barr virus (EBV)‐infected cells by allogeneic nonmyeloablative stem cell transplantation in a patient with the lethal form of chronic active EBV infection , 2004, American journal of hematology.
[23] 敬世 河,et al. Reduced intensity stem cell transplantationを施行した慢性活動性EBウイルス感染症 , 2004 .
[24] E. Jaffe,et al. Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its maturation. , 2004, Blood.
[25] K. Ohta,et al. A case of a long‐time survivor with chronic active Epstein–Barr virus infection , 2004, European journal of haematology.
[26] K. Kawa,et al. [Chronic active Epstein-Barr virus infection treated with reduced intensity stem cell transplantation]. , 2004, [Rinsho ketsueki] The Japanese journal of clinical hematology.
[27] S. Kato,et al. Complete resolution of severe chronic active Epstein–Barr virus infection by cultured, activated donor T lymphocyte infusion after nonmyeloablative stem cells allografting , 2003, Bone Marrow Transplantation.
[28] S. Asano,et al. Successful treatment of natural killer (NK) cell leukemia following a long-standing chronic active Epstein–Barr virus (CAEBV) infection with allogeneic bone marrow transplantation , 2003, Bone Marrow Transplantation.
[29] H. Kanegane,et al. Prognostic factors for chronic active Epstein-Barr virus infection. , 2003, The Journal of infectious diseases.
[30] T. Okamura,et al. Unrelated bone marrow transplantation for Epstein–Barr virus-associated T/NK-cell lymphoproliferative disease , 2003, Bone Marrow Transplantation.
[31] James F. Jones,et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. , 2002, Blood.
[32] R. Hanada,et al. Chronic active Epstein–Barr virus infection (CAEBV) successfully treated with allogeneic peripheral blood stem cell transplantation , 2002, Bone Marrow Transplantation.
[33] T. Okamura,et al. [CD34+ progenitor cell transplantation from HLA-mismatched donors to two patients with chronic active Epstein-Barr virus infection]. , 2001, [Rinsho ketsueki] The Japanese journal of clinical hematology.
[34] Zhensheng Liu,et al. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. , 2001, Transplantation.
[35] H. Kanegane,et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. , 2001, Blood.
[36] H. Takada,et al. Epstein-Barr virus (EBV) load and cytokine gene expression in activated T cells of chronic active EBV infection. , 2000, The Journal of infectious diseases.
[37] K. Takenaka,et al. Allogeneic peripheral blood stem cell transplantation for the treatment of chronic active Epstein–Barr virus infection , 2000, Bone Marrow Transplantation.
[38] E. Jaffe,et al. Fulminant EBV+ T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome , 2000 .
[39] T. Okamura,et al. Blood stem-cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation. , 2000, The Lancet.
[40] E. Jaffe,et al. Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. , 2000, Blood.
[41] J. Henter,et al. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society. , 1999, Blood.
[42] H. Takada,et al. Interferon-α Therapy for Chronic Active Epstein‐Barr Virus Infection: Potential Effect on the Development of T‐Lymphoproliferative Disease , 1998, Journal of pediatric hematology/oncology.
[43] J. Bell,et al. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis , 1996, Nature Medicine.
[44] T. Morishima,et al. Establishment of anti‐Epstein–Barr virus (EBV) cellular immunity by adoptive transfer of virus‐specific cytotoxic T lymphocytes from an HLA‐matched sibling to a patient with severe chronic active EBV infection , 1996, Clinical and experimental immunology.
[45] G. Storch,et al. EPSTEIN‐BARR VIRUS DNA IN PERIPHERAL BLOOD LEUKOCYTES OF PATIENTS WITH POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE , 1995, Transplantation.
[46] M. Fujieda,et al. Defective activity of Epstein‐Barr virus (EBV) specific cytotoxic T lymphocytes in children with chronic active EBV infection and in their parents , 1993, Acta paediatrica Japonica : Overseas edition.
[47] S. Straus. Acute progressive Epstein-Barr virus infections. , 1992, Annual review of medicine.
[48] Y. Sakiyama,et al. Severe chronic active Epstein-Barr virus infection syndrome , 1991, Clinical Microbiology Reviews.
[49] Y. Monczak,et al. Brief report: Killer cell defect and persistent immunological abnormalities in two patients with chronic active epstein‐barr virus infection , 1989, Journal of medical virology.
[50] M. Fujieda,et al. Defective killer cell activity in patients with chronic active Epstein-Barr virus infection. , 1988, Acta medica Okayama.
[51] A. Tawa,et al. SUCCESSFUL TREATMENT OF CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION WITH RECOMBINANT INTERLEUKIN-2 , 1987, The Lancet.
[52] R. Schooley,et al. Chronic Epstein-Barr virus infection associated with fever and interstitial pneumonitis. Clinical and serologic features and response to antiviral chemotherapy. , 1986, Annals of internal medicine.
[53] D. Zych,et al. The Kviem controversy. , 1972, Lancet.